Argus Reiterates “Hold” Rating for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX)‘s stock had its “hold” rating reaffirmed by equities researchers at Argus in a research note issued on Friday,Benzinga reports.

Several other brokerages also recently weighed in on BSX. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 price objective on shares of Boston Scientific in a research report on Thursday. Citigroup reduced their price objective on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday. Oppenheimer decreased their target price on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a report on Monday. Finally, Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, July 25th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Trading Down 0.3%

BSX opened at $45.92 on Friday. The firm has a market capitalization of $68.25 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.89 and a beta of 0.58. Boston Scientific has a one year low of $42.20 and a one year high of $109.50. The business has a 50 day simple moving average of $46.35 and a two-hundred day simple moving average of $62.37. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The business’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts predict that Boston Scientific will post 3.31 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a share buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling

In other Boston Scientific news, Director David C. Habiger purchased 2,250 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares in the company, valued at approximately $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. State Street Corp lifted its stake in shares of Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Capital World Investors grew its position in shares of Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares during the last quarter. Norges Bank acquired a new stake in Boston Scientific in the fourth quarter valued at approximately $2,199,395,000. Finally, Morgan Stanley boosted its holdings in Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded second-quarter expectations, reporting adjusted EPS of $0.86 versus $0.83 expected and revenue of $5.44 billion versus approximately $5.38 billion expected. Revenue increased 7.5% year over year, supported by broad-based cardiovascular growth, international sales and margin expansion. Boston Scientific Q2 Earnings & Revenues Top Estimates
• Positive Sentiment: Management raised its full-year sales-growth outlook to roughly 5.5%–6.5%, while highlighting cost savings, new product launches and a multiyear restructuring plan intended to improve efficiency. The planned restructuring could ultimately generate about $500 million in savings. Boston Scientific Q2 Results, Recall and Restructuring Plan
• Positive Sentiment: Boston Scientific’s pending acquisition of Penumbra adds exposure to thrombectomy and embolization markets. Penumbra reported second-quarter revenue of $390.0 million, up 14.9% year over year, with gross margin improving to 67.9%. Penumbra Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Despite lower targets, UBS, BTIG, TD Cowen and Truist maintained buy ratings. Their revised targets—$74, $60, $56 and $57, respectively—still imply substantial upside, but the reductions signal more cautious near-term expectations. BTIG Lowers Boston Scientific Price Target
• Negative Sentiment: Boston Scientific cut full-year adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41, below the roughly $3.31 consensus midpoint, and set third-quarter EPS guidance at $0.80–$0.82. Softer demand for the WATCHMAN heart-implant portfolio and pressure in electrophysiology were the primary concerns. Boston Scientific Lowers Full-Year Guidance
• Negative Sentiment: The company also disclosed a recall involving its Rapid Refill Continuous Injection System and restructuring costs of up to $800 million. These charges weigh on earnings visibility even though management expects longer-term operating benefits. Boston Scientific Cuts Outlook Ahead of Restructuring

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.